Cargando…

Supply and Clinical Application of Actinium-225 and Bismuth-213

The recent development of (225)Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters (225)Actinium and its daughter nuclide (213)Bismuth include the therapy of brain tumors, bladder...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgenstern, Alfred, Apostolidis, Christos, Bruchertseifer, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	W.B. Saunders 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082773/ https://www.ncbi.nlm.nih.gov/pubmed/32172796 http://dx.doi.org/10.1053/j.semnuclmed.2020.02.003

Ejemplares similares

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

Radium and Francium beam tests to produce 225Ac/ 213Bi generators at CERN-MEDICIS
por: Bruchertseifer, Frank, et al.
Publicado: (2015)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020)

The determination of the radiochemical purity of Actinium-225 radiopharmaceuticals: a conundrum
por: Kleynhans, Janke, et al.
Publicado: (2022)

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2021)

Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity
por: Kratochwil, Clemens, et al.
Publicado: (2021)

Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review
por: Mdanda, Sipho, et al.
Publicado: (2023)

First‐Generation Bispidine Chelators for (213)Bi(III) Radiopharmaceutical Applications
por: Bruchertseifer, Frank, et al.
Publicado: (2020)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with (213)Bi-substance P analogue
por: Krolicki, Leszek, et al.
Publicado: (2018)

Functionalized NaA nanozeolites labeled with (224,225)Ra for targeted alpha therapy
por: Piotrowska, Agata, et al.
Publicado: (2013)

Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model
por: Fichou, Nolwenn, et al.
Publicado: (2015)

α-Zirconium(IV) Phosphate: Static Study of (225)Ac Sorption in an Acidic Environment and Its Kinetic Sorption Study Using (nat)Eu as a Model System for (225)Ac
por: Ondrák, Lukáš, et al.
Publicado: (2023)

A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225
por: Salvanou, Evangelia-Alexandra, et al.
Publicado: (2020)

Optimization of Cation Exchange for the Separation of Actinium-225 from Radioactive Thorium, Radium-223 and Other Metals
por: Fitzsimmons, Jonathan, et al.
Publicado: (2019)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
por: Shi, Mengqi, et al.
Publicado: (2022)

Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227
por: Anderson, Peter M., et al.
Publicado: (2022)

Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin
por: Reissig, Falco, et al.
Publicado: (2022)

Daratumumab-(225)Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors
por: Dawicki, Wojciech, et al.
Publicado: (2019)

Diverse metabolic response of cancer cells treated with a (213)Bi-anti-EGFR-immunoconjugate
por: Feuerecker, Benedikt, et al.
Publicado: (2021)

Functionalized TiO(2) nanoparticles labelled with (225)Ac for targeted alpha radionuclide therapy
por: Cędrowska, Edyta, et al.
Publicado: (2018)

Long-Term Toxicity of (213)Bi-Labelled BSA in Mice
por: Dorso, Laëtitia, et al.
Publicado: (2016)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation
por: Wulbrand, Christian, et al.
Publicado: (2013)

Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA—A Proof of Concept Study
por: Reissig, Falco, et al.
Publicado: (2021)

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics
por: Šimeček, Jakub, et al.
Publicado: (2018)

Assessment of (213)Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-(13)C]pyruvate and [(18)F]FDG
por: Feuerecker, Benedikt, et al.
Publicado: (2019)

Optimizing labelling conditions of (213)Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy
por: Chan, Ho Sze, et al.
Publicado: (2016)

(213)Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
por: Kratochwil, C., et al.
Publicado: (2014)

Dose escalation study of targeted alpha therapy with [(225)Ac]Ac-DOTA-substance P in recurrence glioblastoma – safety and efficacy
por: Królicki, Leszek, et al.
Publicado: (2021)

(225)Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient
por: Aras, Omer, et al.
Publicado: (2021)

Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis
por: Parida, Girish Kumar, et al.
Publicado: (2023)

(225)Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study
por: Sathekge, Mike, et al.
Publicado: (2018)

Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside
por: Ahenkorah, Stephen, et al.
Publicado: (2021)

Alpha Therapy with (225)Actinium Labeled Prostate Specific Membrane Antigen: Reporting New Photopeak of 78 Kilo-electron Volts for Better Image Statistics
por: Rasheed, Rashid, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vtfgqte29grm4d40cb1723pt88